Page 1

  Consolidated Investment Analysis for Bristol‐Myers Squibb  Co.    Bristol Myers Squibb Co. (NYSE: BMY)   Company Description  Bristol‐Myers Squibb Company (BMS) is engaged in the discovery, development, licensing,  manufacturing, marketing, distribution and sale of pharmaceutical products on a global basis.  The Company's products are sold worldwide, primarily to wholesalers, retail pharmacies,  hospitals, government entities and the medical profession. It manufactures products in the  United States, Puerto Rico and in eight foreign countries. In September 2009, BMS acquired  Medarex, Inc., and in December 2009, it divested the Mead Johnson Nutrition Company.  Share Statistics   Symbol      Current Price    52wk Range    Avg Vol (3m)   

BMY    26.04    22.24‐ 28.00  10,408,100 

       

EPS    Market Cap  52wk Change  P/E (ttm) 

       

5.92  44.57B  1.96%  4.40 

Financial Summary 

On October 26, 2010, Bristol Myers Squibb Co reported 3rd quarter 2010 earnings of 0.59 per share. This result exceeded the 0.53 consensus of the 18 analysts covering the company and exceeded last year's 3rd quarter results by 13.46%. Bristol Myers Squibb Co reported annual 2009 earnings of 1.85 per share on January 28, 2010. BMY had 3rd quarter 2010 revenues of 4.80bn. This missed the 4.92bn consensus estimate of the 16 analysts following the company. This was 0.63% above the prior year's 3rd quarter results. BMY had revenues for the full year 2009 of 18.81bn. This was -8.69% below the prior year's results.


Analyst Consensus  Buy

Outperform

Hold

Underperform

Sell

No Opinion

This is the consensus forecast amongst 21 polled investment analysts. Against the Bristol-Myers Squibb Co company. Analyst Detail

Buy

Outperform

Hold

Underperform

Sell

No Opinion

Latest

6

3

10

0

2

0

4 weeks ago

7

3

9

0

2

0

2 months ago

6

3

10

0

2

0

3 months ago

7

4

10

0

1

0

Last year

3

1

11

0

1

0

The 17 analysts offering 12 month price targets for Bristol Myers Squibb Co (BMY:NYQ) have a median target of 27.00, with a high estimate of 31.50 and a low estimate of 20.20. The median estimate represents a 4.25% increase from the last price of 25.90. Technical Analysis Chart 

   


Consolidated Investment Analysis for Cisco Systems Inc.  Cisco Systems, Inc. (NASDAQ: CSCO)  Company Description  Cisco Systems, Inc. designs, manufactures and sells Internet protocol (IP)‐based networking and  other products related to the communications and information technology (IT) industry, and  provides services associated with these products and their use. The Company provides a line of  products for transporting data, voice, and video within buildings, across campuses, and around  the world. Its products are designed to transform how people connect, communicate and  collaborate. The Company's products are installed at enterprise businesses, public institutions,  telecommunications companies, commercial businesses and personal residences. It has five  segments: United States and Canada, European Markets, Emerging Markets, Asia Pacific, and  Japan. The Emerging Markets theater consists of Eastern Europe, Latin America, the Middle East  and Africa and Russia and the Commonwealth of Independent States. In December 2009, the  Company completed its acquisition of Starent Networks.  Share Statistics  Symbol    CSCO    Current Price  19.70    52wk Range  19.00‐ 27.74  Avg Vol (3m)  71,498,700 

       

EPS    Market Cap  52wk Change  P/E (ttm) 

1.36  109.19B  ‐17.71%  14.44 

Financial Summary 

On November 10, 2010, Cisco Systems Inc reported 1st quarter 2011 earnings of 0.42 per share. This result exceeded the 0.40 consensus of the 38 analysts covering the company and exceeded last year's 1st quarter results by 16.67%. The next earnings announcement is expected on February 09, 2011. Cisco Systems Inc reported annual 2010 earnings of 1.61 per share on August 11, 2010 CSCO.O had 1st quarter 2011 revenues of 10.75bn. This bettered the 10.74bn consensus of the 37 analysts covering the company. This was -0.79% below the prior year's 1st quarter results. CSCO.O had revenues for the full year 2010 of 40.04bn. This was 10.86% above the prior year's results.  


Analyst Consensus  Buy

Outperform

Hold

Underperform

Sell

No Opinion

This is the consensus forecast amongst 44 polled investment analysts. Against the Cisco Systems Inc company. Analyst Detail

Buy

Outperform

Hold

Underperform

Sell

No Opinion

Latest

21

8

14

1

0

0

4 weeks ago

19

8

14

1

1

0

2 months ago

22

10

9

0

1

0

3 months ago

22

10

9

0

1

0

Last year

17

8

9

0

1

2

The 36 analysts offering 12 month price targets for Cisco Systems Inc (CSCO:NSQ) have a median target of 25.00, with a high estimate of 28.00 and a low estimate of 17.00. The median estimate represents a 26.90% increase from the last price of 19.70. Technical Analysis Chart 

   


Consolidated Investment Analysis for Cell Therapeutics Inc.  Cell Therapeutics, Inc. (NASDAQ:CTIC)  Company Description  Cell Therapeutics, Inc. (Cell Therapeutics) develops, acquires and commercializes treatments for  cancer. The Company's research, development, acquisition and in‐licensing activities  concentrate on identifying and developing new, less toxic and effective ways to treat cancer.  Cell Therapeutics is developing pixantrone (BBR 2778), a deoxyribonucleic acid (DNA) major  groove binder with an aza‐anthracenedione molecular structure, differentiating it from  anthracycline chemotherapy agents. A new chemical compound for the treatment of non‐ Hodgkin's lymphoma (NHL), and various other hematologic malignancies, solid tumors, and  immunological disorders, pixantrone is being developed to improve activity and safety in  treating cancers treated with the anthracycline family of anti‐cancer agents. It is developing  OPAXIO (paclitaxel poliglumex), which was previously referred to as XYOTAX, for the treatment  of non‐small cell lung cancer (NSCLC), and ovarian cancer.  Share Statistics  Symbol    Current Price  52wk Range  Avg Vol (3m) 

CTIC    0.37    0.12‐ 1.40  3,052,730 

       

       

EPS    Market Cap   52wk Change  P/E (ttm) 

‐0.22  304.32M  ‐66.95%  N/A 

Financial Summary 

On October 28, 2010, Cell Therapeutics Inc reported 3rd quarter 2010 losses of 0.02 per share. The next earnings announcement is expected on February 07, 2011. Cell Therapeutics Inc reported annual 2009 losses of -0.25 per share on February 11, 2010. The next earnings announcement from Cell Therapeutics Inc is expected the week of February 07, 2011. CTIC.O did not report revenues for the 3rd quarter 2010. However, during the 3rd quarter of the prior year the company reported revenues of 299.00k. CTIC.O had revenues for the full year 2009 of 80.00k. This was -99.30% below the prior year's results. 


Analyst Consensus  Buy

Outperform

Hold

Underperform

Sell

No Opinion

This is the consensus forecast amongst 2 polled investment analysts. Against the Cell Therapeutics Inc company. Analyst Detail

Buy

Outperform

Hold

Underperform

Sell

No Opinion

Latest

0

1

1

0

0

1

4 weeks ago

0

2

0

0

0

1

2 months ago

0

1

1

0

0

1

3 months ago

0

1

1

0

0

1

Last year

0

2

0

0

0

1

  Technical Analysis 

       


Report Disclaimer  DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR  IN ONE OF OUR NEWSLETTERS. We are not registered as a securities broker‐dealer or an  investment advisor either within the U.S. Securities and Exchange Commission (the “SEC”) or  with any state securities regulatory authority. We are neither licensed nor qualified to provide  investment advice.  The information contained on our website or in any of our newsletters should be viewed as  commercial advertisement and is not intended to be investment advice. Any information found  on our website, or in any of our newsletters is not provided to any particular individual with a  view toward their individual circumstances. The information contained on our website, and in  any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions,  comments, and information free of charge exclusively to individuals who wish to receive them.  Our newsletter and website have been prepared for informational purposes only and are not  intended to be used as a complete source of information on any particular company. An  individual should never invest in the securities of any of the companies profiled based solely on  information contained in our report. Individuals should assume that all information contained  on our website or in one of our newsletters about profiled companies is not trustworthy unless  verified by their own independent research.  Any individual who chooses to invest in any securities should do so with caution. Investing in  securities is speculative and carries a high degree of risk; you may lose some or all of the money  that is invested. Always research your own investments and consult with a registered  investment adviser or licensed stock broker before investing.  This report is a service of Seo Freisin, Inc., a financial public relations firm that has been  compensated by the companies profiled. All direct and third party compensation received has  been disclosed on both, this newsletter, and on our website in accordance with section 17(b) of  the Securities Act of 1933. This compensation constitutes a conflict of interest as to our ability to   remain objective in our communication regarding the profiled companies. Seo Freisin, Inc.,  and/or its affiliates will hold, buy, and sell securities in the companies profiled. When  compensated in shares, all readers should be aware that it is our policy to liquidate   all shares immediately. We reserve the right to buy or sell the shares of any the companies  mentioned in any materials we produce at any time. This compensation constitutes a conflict of  interest as to our ability to remain objective in our communication regarding the profiled  companies.   ChartPoppers.com is a Web site wholly‐owned by Seo Freisin, Inc. Seo Freisin, Inc., has not been  compensated for any of the Companies mentioned in this report, we also do not own any shares  in the companies discussed in this report. 


Information contained in our report will contain “forward looking statements” as defined under  section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and  uncertainties outside of our control that could cause actual operations or results to differ  materially from those anticipated. Factors that could affect performance include, but are not  limited to, those factors that are discussed in each profiled company’s most recent reports or  registration statements filed with the SEC. You should consider these factors in evaluating the  forward looking statements included in the report and not place undue reliance upon such  statements.  We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the  information provided, including information regarding a profiled company’s plans or ability to  effect any planned or proposed actions. We have no first‐hand knowledge of any profiled  company’s operations and therefore cannot comment on their capabilities, intent, resources,  nor experience and we make no attempt to do so. Statistical information, dollar amounts, and  market size data was provided by the subject company and related sources which we believe to  be reliable.  To the fullest extent of the law, we will not be liable to any person or entity for the quality,  accuracy, completeness, reliability, or timeliness of the information provided in this report, or  for any direct, indirect, consequential, incidental, special or punitive damages that may arise out  of the use of information we provide to any person or entity (including, but not limited to, lost  profits, loss opportunities, trading losses, and damages that may result from any inaccuracy or  incompleteness of this information).  We encourage you to invest carefully and read investment information available at the websites  of the SEC at http://www.sec.gov and FINRA at http://www.finra.org         


BMY, CSCO, CTIC  

BMY had revenues for the full year 2009 of 18.81bn. This was -8.69% below the prior year's results. Company Description Financial Summary Br...

Advertisement
Read more
Read more
Similar to
Popular now
Just for you